T tropic virus

Abstract To investigate the basis for envelope Env determinants influencing simian immunodeficiency virus SIV tropism, we studied a number of Envs that are closely related to that of SIVmac, a pathogenic, T-tropic virus that is neutralization resistant.

Publication types Research Support, Non-U. Gov't Research Support, U. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.

A seven-transmembrane domain receptor involved in fusion and entry of T cell—tropic human immunodeficiency virus type—1 strains. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins MCP-2 and MCP-3 belonging to the chemokine family. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivoimflammatory properties.

Expression of a human mutant monocyte chemotactic protein 3 in Pichia pastorisand characterization as an MCP-3 receptor antagonist. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor CXCR4 is both cell type and virus strain dependent. A highly efficacious lymphocyte chemoattractant stromal cell—derived factor 1 SDF Monocyte chemoattractant protein—3 is a functional ligand for CC chemokine receptors 1 and 2b.

Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell—tropic virus population. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. Figure 1. View large Download slide.

Figure 2. Figure 4. Figure 3. Coreceptor used. View Large. AMD first. Materials And Methods. Volume , Issue 8.

Previous Article Next Article. View Metrics. Blocking Chemokine Receptors. Email alerts Article Activity Alert. Complete Issue Alert. Appended to this Agent Summary Statement is a statement Addendum 1 issued by CDC on the use of all human control or reagent sera shipped to other laboratories.

The Food and Drug Administration requires that manufacturers of human serum reagents use a similarly worded statement. Laboratory coats, gowns, or uniforms should be worn by laboratory workers, as is customary for other BSL 2 or 3 practices, depending on the nature of the work, concentration of the virus, and volume of material being handled. Because many animals bite, and some throw feces, urine, or expectorate at humans, animal-care personnel must wear coats, protective gloves, coveralls or uniforms, and face shields as appropriate to protect the skin and mucous membranes of the eyes, nose, and mouth from potential exposure to these substances when working with animals likely to manifest such behavior.

Incineration of solid wastes may be used as an alternate method of disposal. Work surfaces should be decontaminated at the end of each day on completion of procedures or when overly contaminated.

Many commonly used chemical disinfectants with such active ingredients as sodium hypo- chlorite, formaldehyde, glutaraldehyde, or phenols 4, can be used to decontaminate laboratory work surfaces; they can also be used to decontaminate some laboratory instruments, specific areas of contaminated laboratory clothing, and spills of infectious materials.

Prompt decontam- ination of spills and other overt contamination should be standard practice. Similarly, results of chemical analyses or antibody assays may vary when sera are heated before testing according to the analysis or assay being performed As part of an ongoing medical surveillance program for employees, all laboratory workers before being assigned to activities with a high potential for exposure should have a serum sample obtained and stored at C -4Q F for possible future testing.

Subsequent serum samples should be obtained and stored in accordance with laboratory policy or following an inadvertent laboratory exposure involving materials described above. Furthermore, the physician requesting serologic testing of these serum specimens must first obtain informed consent from the laboratory worker and describe the confidentiality safeguards available to protect test results.

The laboratory workers whose serum specimens are to be tested should understand how the test results are to be used, the implications of a positive or negative test result, and the limits, if any, of the confidentiality safeguards. Biosafety in microbiological and biomedical laboratories, CDC MMWR ; MMWR ;, Acquired immune deficiency syndrome AIDS : precautions for clinical and laboratory staffs.

Revision of the case definition of acquired immunodeficiency syndrome for national reporting -- United States. JAMA ; Lancet ;ii Ann Intern Med ; New Engl J Med ;